Activity and safety of mobocertinib (Tak-788) in previously treated non–small cell lung cancer with egfr exon 20 insertion mutations from a phase i/ii trial

Gregory J. Riely, Joel W. Neal, D. Ross Camidge, Alexander I. Spira, Zofia Piotrowska, Daniel B. Costa, Anne S. Tsao, Jyoti D. Patel, Shirish M. Gadgeel, Lyudmila Bazhenova, Viola W. Zhu, Howard L. West, Tarek Mekhail, Ryan D. Gentzler, Danny Nguyen, Sylvie Vincent, Steven Zhang, Jianchang Lin, Veronica Bunn, Shu JinShuanglian Li, Pasi A. Jänne

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Activity and safety of mobocertinib (Tak-788) in previously treated non–small cell lung cancer with egfr exon 20 insertion mutations from a phase i/ii trial'. Together they form a unique fingerprint.

Medicine & Life Sciences